Merck (NYSE: MRK) has announced a definitive agreement with the intention to acquire HUB Organoids Holding B.V. (HUB), a company specializing in organoid technology. Organoids, which are cell culture models that functionally resemble organs, hold the potential to revolutionize drug development by accelerating processes, enhancing disease treatment understanding across diverse populations, and reducing the industry’s dependence on animal testing. The transaction is anticipated to be completed by the end of December 2024.
HUB’s Pioneering Role in Organoid Technology
Based in Utrecht, Netherlands, HUB is a leader in the field of organoids, employing approximately 70 people. The acquisition of HUB will significantly bolster Merck’s existing 2D and 3D cell culture portfolio, providing valuable tools and benchtop instruments for academic, biotech, and pharmaceutical customers. This move by Merck underscores its commitment to investing in innovative technologies that can drive scientific advancements and improve healthcare outcomes.
Enhancing Merck’s Cell Culture Portfolio
The integration of HUB’s organoid technology into Merck’s offerings will enhance the company’s ability to provide comprehensive solutions for life science research. This acquisition aligns with Merck’s strategy to expand its presence in the cell culture market and to offer cutting-edge technologies that can support the development of more effective and targeted therapies.-Fineline Info & Tech
